MCID: HYP082
MIFTS: 47

Hypopharynx Cancer

Categories: Rare diseases, Cancer diseases, Oral diseases

Aliases & Classifications for Hypopharynx Cancer

MalaCards integrated aliases for Hypopharynx Cancer:

Name: Hypopharynx Cancer 12 14
Hypopharyngeal Cancer 12 49 51 69
Hypopharyngeal Neoplasms 41 69
Malignant Neoplasm of Ill-Defined Sites Within the Lip and Oral Cavity 12
Malignant Neoplasm of Other Specified Sites of Hypopharynx 12
Malignant Neoplasm of Other Specified Hypopharyngeal Site 12
Malignant Neoplasm of Posterior Hypopharyngeal Wall 12
Malignant Neoplasm of Posterior Wall of Hypopharynx 12
Malignant Tumor of Posterior Wall of Hypopharynx 12
Malignant Neoplasm of Hypopharynx, Nos 12
Malignant Neoplasm of Hypopharynx Nos 12
Malignant Neoplasm of Hypopharynx 12
Malignant Tumour of Hypopharynx 12
Malignant Hypopharyngeal Tumor 12
Malignant Tumor of Hypopharynx 12
Hypopharyngeal Carcinoma 69

Classifications:



Summaries for Hypopharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary : Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to gum cancer and oropharynx cancer. An important gene associated with Hypopharynx Cancer is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are FGF signaling pathway and Arf6 trafficking events. The drugs Dopamine and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include the hypopharynx, lung and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Hypopharyngeal cancer is a disease in which malignant cells grow in the hypopharynx (the area where the... more...

Related Diseases for Hypopharynx Cancer

Diseases related to Hypopharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 31)
# Related Disease Score Top Affiliating Genes
1 gum cancer 10.3 MMP8 SMUG1
2 oropharynx cancer 10.2 MMP8 SMUG1
3 lipid pneumonia 10.2 MMP8 SMUG1
4 postcricoid region cancer 10.1
5 aryepiglottic fold cancer 10.1
6 gastric signet ring cell adenocarcinoma 9.9 CDH1 SMUG1
7 lung giant cell carcinoma 9.9 CDH1 NME1
8 parotid gland cancer 9.9 CDH1 MET
9 papillary adenocarcinoma 9.9 CDH1 NME1
10 breast ductal carcinoma 9.8 CDH1 MET NME1
11 salivary gland cancer 9.8 AREG MET
12 gastric adenocarcinoma 9.7 CDH1 MET NME1
13 aging 9.7
14 laryngitis 9.7
15 laryngeal cleft 9.7
16 gastrointestinal system benign neoplasm 9.7 AREG CDH1
17 intestinal benign neoplasm 9.7 AREG CDH1
18 malignant ovarian surface epithelial-stromal neoplasm 9.6 AREG CDH1 NME1
19 ovary epithelial cancer 9.6 AREG CDH1 NME1
20 ovarian cancer 1 9.6 AREG CDH1 NME1
21 tongue cancer 9.6 CDH1 MMP8
22 female reproductive organ cancer 9.6 AREG CDH1 SMUG1
23 endocrine gland cancer 9.6 AREG CDH1 SMUG1
24 squamous cell carcinoma, head and neck 9.6 AREG CDH1 MET
25 reproductive organ cancer 9.6 AREG CDH1 SMUG1
26 cell type cancer 9.6 AREG CDH1 SMUG1
27 renal cell carcinoma, nonpapillary 9.5 CDH1 MET NME1
28 gastrointestinal system cancer 9.4 AREG CDH1 MET SMUG1
29 pharynx cancer 9.3 AREG CDH1 MMP8 SMUG1
30 ovarian cancer 9.2 AREG CDH1 MET NME1
31 gastric cancer 9.0 AREG CDH1 CNDP2 MET NME1

Comorbidity relations with Hypopharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer

Symptoms & Phenotypes for Hypopharynx Cancer

GenomeRNAi Phenotypes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

25 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.62 MMP8
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.62 MSMO1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.62 MSMO1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.62 MSMO1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.62 GNB1L
6 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.62 MMP8
7 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.62 MMP8 MSMO1 GNB1L
8 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.62 MMP8
9 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.62 MSMO1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.62 MMP8
11 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.62 GNB1L
12 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.62 MMP8
13 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.62 MMP8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.62 MSMO1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.62 MMP8
16 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.62 GNB1L
17 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.62 GNB1L
18 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.62 MMP8

MGI Mouse Phenotypes related to Hypopharynx Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 CDH1 MET MMP8 NME1 SMUG1

Drugs & Therapeutics for Hypopharynx Cancer

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 284)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
2
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
3
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
10 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
11 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
12 Nicotinic Agonists Phase 4,Not Applicable
13 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
14 Dopamine Agents Phase 4,Phase 2
15 Dopamine Uptake Inhibitors Phase 4,Phase 2
16 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antidepressive Agents, Second-Generation Phase 4,Phase 2
18 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
19
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
20
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 2767 441203 84093
21
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
22
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
23
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 205923-56-4 56842117 2333
24
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
25
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
26
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
27 Racepinephrine Approved Phase 3,Phase 2 329-65-7
28
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
29
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
30
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
31
Histamine Approved, Investigational Phase 3,Not Applicable 51-45-6, 75614-87-8 774
32
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
33
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
34
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
35
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
36
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5282379 5538
37
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
38
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
39
Doxepin Approved, Investigational Phase 3,Not Applicable 1668-19-5 667468 667477
40
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
41
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
42
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
43 Tocopherol Approved, Investigational, Nutraceutical Phase 3
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
45
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
46 Kava Approved, Investigational, Nutraceutical Phase 3,Phase 2 9000-38-8
47
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
48 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
49 Analgesics Phase 3,Phase 2,Phase 1
50
s 1 (combination) Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 349)

# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
4 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
5 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
6 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
7 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
8 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
9 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL
10 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
11 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
12 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
13 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
14 Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx Completed NCT00002839 Phase 3 cisplatin;fluorouracil
15 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
16 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
18 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
19 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
20 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
21 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
22 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
23 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
24 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
25 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
26 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
27 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
28 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
29 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
30 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
31 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
32 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
33 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
34 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
35 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
36 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
37 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
38 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
40 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
41 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
42 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
43 Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
44 Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer Recruiting NCT01772706 Phase 3
45 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
46 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
47 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
48 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
49 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Active, not recruiting NCT00265941 Phase 3 cetuximab;cisplatin
50 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer Active, not recruiting NCT00047008 Phase 3 cisplatin

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Genetic Tests for Hypopharynx Cancer

Anatomical Context for Hypopharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Hypopharynx Cancer:

18
The Hypopharynx

MalaCards organs/tissues related to Hypopharynx Cancer:

38
Lung, Breast, Testes, Prostate, Endothelial, Thyroid, Liver

Publications for Hypopharynx Cancer

Articles related to Hypopharynx Cancer:

(show all 24)
# Title Authors Year
1
Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. ( 29080963 )
2018
2
Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer. ( 29018502 )
2017
3
Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study. ( 27825651 )
2017
4
The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy. ( 29259311 )
2017
5
A case of adult congenital laryngeal cleft asymptomatic until hypopharynx cancer treatment. ( 28943051 )
2017
6
Comparative planning of flattening-filter-free and flat beam IMRT for hypopharynx cancer as a function of beam and segment number. ( 24722621 )
2014
7
HPV: a factor in organ preservation for locally advanced larynx and hypopharynx cancer? ( 24119488 )
2014
8
Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell. ( 24294361 )
2013
9
Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer - results of a matched-pair analysis. ( 21726998 )
2011
10
Videostroboscopic and morphological aspects of voice disturbances in patients with larynx atrophy and coexisting hypopharynx cancer. ( 22252761 )
2011
11
Impact of combination therapy on disease free survival in hypopharynx cancer. ( 21340251 )
2010
12
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. ( 19179556 )
2009
13
The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer. ( 18392505 )
2008
14
Morphological aspect of voice disturbances of aged persons coexisting hypopharynx cancer. ( 17951171 )
2007
15
Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. ( 17290070 )
2007
16
The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. ( 15930601 )
2005
17
Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. ( 15743695 )
2005
18
Occupation and larynx and hypopharynx cancer: a job-exposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. ( 12814200 )
2003
19
Occupation and larynx and hypopharynx cancer: an international case-control study in France, Italy, Spain, and Switzerland. ( 12814199 )
2003
20
Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. ( 11291134 )
2001
21
Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. ( 10037284 )
1999
22
Endoscopic treatment of supraglottic and hypopharynx cancer. ( 8295459 )
1994
23
Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. ( 8028939 )
1994
24
SURGICAL TREATMENT OF LARYNX AND HYPOPHARYNX CANCER. ( 14090428 )
1964

Variations for Hypopharynx Cancer

Expression for Hypopharynx Cancer

Search GEO for disease gene expression data for Hypopharynx Cancer.

Pathways for Hypopharynx Cancer

GO Terms for Hypopharynx Cancer

Cellular components related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic side of plasma membrane GO:0009898 8.62 CDH1 GNB1L

Biological processes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to cAMP GO:0051591 8.96 AREG NME1
2 entry of bacterium into host cell GO:0035635 8.62 CDH1 MET

Sources for Hypopharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....